Case study shows importance of single-pill HIV-1 treatment

July 17, 2014
Case study shows importance of single-pill HIV-1 treatment

(HealthDay)—A single-pill combination HIV-1 treatment may be appropriate in certain cases, according to a case vignette published in the July 17 issue of the New England Journal of Medicine.

Monica Gandhi, M.D., M.P.H., from the University of California in San Francisco, and Rajesh T. Gandhi, M.D., from Massachusetts General Hospital in Boston, discuss the case of a 52-year-old homeless man who was diagnosed with HIV-1 infection in 2005. The patient was recently prescribed a multi-pill antiretroviral regimen, which he had not followed. The patient, who did not take other medications and had normal renal function, would take his medication if it was limited to a single pill once a day.

The authors discuss the currently available single-pill combinations marketed for HIV-1 treatment, each of which contains the same combination of one nucleotide reverse-transcriptase inhibitor and one nucleoside reverse-transcriptase inhibitor. After checking the HIV-1 genotype of the patient for drug resistance, a single-pill combination could be beneficial in this case. Tenofovir disoproxil fumarate and emtricitabine would be a reasonable option as a backbone in the single-pill combination, and any of the anchor drugs would be suitable for this patient, based on his having normal .

"The selection of a regimen should be based on potential side effects, food requirements, dosing schedule, and, possibly, anticipated adherence; cost may also be a consideration," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Explore further: UNAIDS welcomes US approval of drug to stop HIV

More information: Full Text (subscription or payment may be required)

Related Stories

Changes in generic pill color and shape disrupt use

July 14, 2014

Generic versions of the same prescription drug are clinically interchangeable but often look different depending on the manufacturer. The FDA does not require consistent pill appearance among interchangeable generic drugs, ...

Recommended for you

Broadly neutralizing HIV antibodies pave the way for vaccine

September 26, 2016

A small number of people infected with HIV produce antibodies with an amazing effect: Not only are the antibodies directed against the own virus strain, but also against different sub-types of HIV that circulate worldwide. ...

Targeting dormant HIV

September 19, 2016

Discovery of a novel, advanced technique to identify the rare cells where human immunodeficiency virus (HIV) hides in patients taking antiretroviral therapy (ART). This is an important step forward in the search for a HIV/AIDS ...

Training human antibodies to protect against HIV

September 8, 2016

During HIV infection, the virus mutates too rapidly for the immune system to combat, but some people produce antibodies that can recognize the virus even two years after infection. With an eye towards developing a vaccine, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.